DBV Technologies (DBVT)
(Delayed Data from NSDQ)
$0.97 USD
+0.02 (2.11%)
Updated Aug 2, 2024 03:20 PM ET
3-Hold of 5 3
F Value F Growth B Momentum F VGM
Brokerage Reports
DBV Technologies S.A. [DBVT]
Reports for Purchase
Showing records 1 - 20 ( 48 total )
Company: DBV Technologies S.A.
Industry: Medical - Biomedical and Genetics
BLA Submission on the Horizon - Remain Optimistic on Viaskin; Reducing PT to $5, Reit. Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: DBV Technologies S.A.
Industry: Medical - Biomedical and Genetics
Viaskin Closer to Sticking-Supplemental Safety Trials on Near-Term Horizon; Reit. Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: DBV Technologies S.A.
Industry: Medical - Biomedical and Genetics
Injectable Food Allergy Label Extension - An Apples to Oranges Comparison to Viaskin;
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: DBV Technologies S.A.
Industry: Medical - Biomedical and Genetics
Positive EPITOPE OLE Data in Toddlers; COMFORT Toddlers Trial De-Risking; Reit. Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: DBV Technologies S.A.
Industry: Medical - Biomedical and Genetics
Viaskin Patch Execution With FDA Protocol Feedback - Looking to 1Q24 Enrollment; Reit Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: DBV Technologies S.A.
Industry: Medical - Biomedical and Genetics
Next Steps for Viaskin Peanut-Type C Meeting Safety Studies That Can Stick; Reit Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: DBV Technologies S.A.
Industry: Medical - Biomedical and Genetics
Considerations on Defined Paths Forward for Viaskin Patch; Reit. Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: DBV Technologies S.A.
Industry: Medical - Biomedical and Genetics
Next Near-Term Steps For Viaskin and Looking to EPITOPE Success; Reit Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: DBV Technologies S.A.
Industry: Medical - Biomedical and Genetics
Engagement With FDA Can Get VITESSE Trial to Stick; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: DBV Technologies S.A.
Industry: Medical - Biomedical and Genetics
Phase 3 VITESSE Trial Initiation-Positioning of Viaskin Peanut for Success
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: DBV Technologies S.A.
Industry: Medical - Biomedical and Genetics
Phase 3 VITESSE Trial Clarity to Define Near-Term Viaskin Advancement
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: DBV Technologies S.A.
Industry: Medical - Biomedical and Genetics
Phase 3 EPITOPE Trial Affirms Viaskin Benefit in Toddlers; Next Sights on Modified Patch
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: DBV Technologies S.A.
Industry: Medical - Biomedical and Genetics
Viaskin Peanut Type C Meeting?A Viable Path to 2Q22 Agency Alignment
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: DBV Technologies S.A.
Industry: Medical - Biomedical and Genetics
Finalizing a Pivotal Viaskin Protocol That Can Stick; Expecting 2022 Clarity
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: DBV Technologies S.A.
Industry: Medical - Biomedical and Genetics
Viaskin Modified Patch Clarity, Albeit in Form of New Pivotal Trial; PT to $10
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: DBV Technologies S.A.
Industry: Medical - Biomedical and Genetics
Viaskin Patch Regulatory Update Shifts to Stepwise Advancement
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: DBV Technologies S.A.
Industry: Medical - Biomedical and Genetics
Company: DBV Technologies S.A.
Industry: Medical - Biomedical and Genetics
We Maintain Lead Viaskin Program Can Find Adhesion; Reit Buy and $14 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: DBV Technologies S.A.
Industry: Medical - Biomedical and Genetics
A Viaskin Peanut Strategy on the Horizon That Can Stick - Our Thoughts
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: DBV Technologies S.A.
Industry: Medical - Biomedical and Genetics
Elucidated Next Steps As Viaskin Modification is Front and Center
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A